HPLC analysis of indomethacin and its impurities in capsule and suppository formulations.
E Kwong, G K Pillai, K M McErlane
文献索引:J. Pharm. Sci. 71(7) , 828-30, (1982)
全文:HTML全文
摘要
Indomethacin and its impurities in suppository and capsule formulations were quantitatively determined by HPLC using a reversed-phase, octadecyl column and a mobile phase of methanol-water-acetonitrile-acetic acid (55:35:10:1). Analysis of the suppository formulations provided a mean potency for indomethacin of 103.8%. The same formulation was found to contain 4-chlorobenzoic acid (0.02%), 5-methoxy-2-methyl-3-indoleacetic acid (0.07%), 4-chlorobenzoic acid-alpha-monoglyceride (0.39%), and indomethacin-alpha-monoglyceride (0.9%) as impurities. The latter two impurities were a result of the interaction of indomethacin and 4-chlorobenzoic acid with glycerin used in the suppository base. Capsule formulations were likewise assayed with an average potency of 99.9 and 101.5% for 25- and 50-mg dosage forms, respectively. Only one of the two capsule formulations examined contained detectable quantities of 4-chlorobenzoic acid (0.05%).
相关化合物
相关文献:
2004-06-15
[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 805(2) , 223-34, (2004)]
2001-01-01
[J. AOAC Int. 84(6) , 1703-7, (2001)]
2004-08-01
[Eur. J. Neurosci. 20(3) , 671-83, (2004)]
1994-09-01
[Cell Growth Differ. 5(9) , 1005-14, (1994)]
[J. Chromatogr. A. 306 , 315-21, (1984)]